Home   ->   news   ->   Press Releases

Press Releases

WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testin

PHILADELPHIA, USA – August 17, 2008 – WuXi AppTec, Inc., the operating company of WuXi PharmaTech (NYSE: WX) in the U.S., has announced the appointments of Garry Takle, Ph.D. as Vice President of Operations and Joseph Hughes, Ph.D. as Vice President of Testing Services for its Philadelphia facility.

Dr. Takle has been with the company for nine years in roles of increasing responsibility at the Philadelphia site, most recently as Vice President of R&D Testing. He has over 20 years' experience in the biopharm/biotech industry and previously worked at Wellcome (now GSK UK), the Rockefeller University and Innovir. Dr. Takle received his Ph.D. in Cellular Immunology from the University of Glasgow.

In his new position, Dr. Takle will focus on continuous improvements in operations at the Philadelphia facility and will have overall responsibility for biologics manufacturing services.
Dr. Hughes has been with the company for over 10 years in various leadership capacities. He has over 29 years' experience in the industry, including previous positions at Merck Sharp and Dohme Research Laboratories and at Sterling Winthrop. Dr. Hughes received his Ph.D. in Microbiology from Northwestern University.

In his new position, Dr. Hughes will take on direct management of all of the testing laboratories at the Philadelphia facility and also work to expand WuXi AppTec's biologics services and client base.
Both Dr. Takle and Dr. Hughes will report directly to Edward Hu, Chief Operating Officer of WuXi PharmaTech.

"Expanding my role at the WuXi AppTec Philadelphia site is an exciting opportunity," said Dr. Takle, "and I look forward to working with our excellent team on the continuing goal of making this facility the best in its class for outsourced process development and contract manufacturing."
"I am very excited to lead all the Philadelphia laboratories as we continue expansion of our capabilities and capacities to provide the biologics industry with the highest quality in testing services," said Dr. Hughes.

"WuXi AppTec is fortunate to have two such experienced and talented managers within our organization to tap for these important roles," said Mr. Hu. "Their deep understanding of the industry, their many years with the company and their proven track record as leaders will be tremendous assets as the Philadelphia facility continues to grow and strengthen its services for the biologics industry."

About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.

back to top